Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells

Plastic and Reconstructive Surgery

Volumn 122, Issue 4, 2008, Pages 1025-1035

  Gevorgyan, Artur ^a   Sukhu, Balram ^a   Alman, Benjamin A ^a   Bristow, Robert G ^a   Pang, Cho Y ^a   Forrest, Christopher R ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALKALINE PHOSPHATASE; AMIFOSTINE; COLLAGEN TYPE 1; OSTEOCALCIN; OSTEOPONTIN; RADIOPROTECTIVE AGENT;

ANIMAL CELL; ARTICLE; BONE GROWTH; CALVARIA; CELL CULTURE; CELL FUNCTION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMING CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; GAMMA RADIATION; GENE EXPRESSION; GROWTH RETARDATION; IN VITRO STUDY; IRRADIATION; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PROTECTION; RADIATION RESPONSE; ANIMAL; ANIMAL MODEL; CELL LINE; DRUG EFFECT; RADIATION EXPOSURE; SKULL;

AMIFOSTINE; ANIMALS; ANIMALS, NEWBORN; CELL LINE; GAMMA RAYS; MICE; MODELS, ANIMAL; OSTEOBLASTS; RADIATION-PROTECTIVE AGENTS; SKULL;

EID: 53149095437     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181845931     Document Type: Article

References (52)

1. Guyuron, B., Dagys, A. P., Munro, I. R., and Ross, R. B. Effect of irradiation on facial growth: A 7- to 25-year follow-up. Ann. Plast. Surg. 11: 423, 1983.
2. Paulino, A. C., Simon, J. H., Zhen, W., and Wen, B. C. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Biol. Phys. 48: 1489, 2000.
3. Denys, D., Kaste, S. C., Kun, L. E., Chaudhary, M. A., Bowman, L. C., and Robbins, K. T. The effects of radiation on craniofacial skeletal growth: A quantitative study. Int. J. Pediatr. Otorhinolaryngol. 45: 7, 1998.
4. Cohen, S. R., Bartlett, S. P., and Whitaker, L. A. Reconstruction of late craniofacial deformities after irradiation of the head and face during childhood. Plast. Reconstr. Surg. 86: 229, 1990.
5. Jackson, I. T., Carls, F., Bush, K., et al. Assessment and treatment of facial deformity resulting from radiation to the orbital area in childhood. Plast. Reconstr. Surg. 98: 1169, 1996.
6. Tamurian, R. M., Damron, T. A., and Spadaro, J. A. Sparing radiation-induced damage to the physis by radioprotectant drugs: Laboratory analysis in a rat model. J. Orthop. Res. 17: 286, 1999.
7. Damron, T. A., Spadaro, J. A., Margulies, B., and Damron, L. A. Dose response of amifostine in protection of growth plate function from irradiation effects. Int. J. Cancer 90: 73, 2000.
8. Damron,T. A., Spadaro,J.A., Tamurian,R. M., and Damron, L. A. Sparing of radiation-induced damage to the physis: Fractionation alone compared to amifostine pretreatment. Int. J. Radiat. Oncol. Biol. Phys. 47: 1067, 2000.
9. Damron, T. A., Margulies, B., Biskup, D., and Spadaro, J. A. Amifostine before fractionated irradiation protects bone growth in rats better than fractionation alone. Int. J. Radiat. Oncol. Biol. Phys. 50: 479, 2001.
10. Spadaro, J. A., Baesl, M. T., Conta, A. C., Margulies, B. M., and Damron, T. A. Effects of irradiation on the appositional and longitudinal growth of the tibia and fibula of the rat with and without radioprotectant. J. Pediatr. Orthop. 23: 35, 2003.
11. Damron, T. A., Margulies, B. S., Strauss, J. A., O'Hara, K., Spadaro, J. A., and Farnum, C. E. Sequential histomorphometric analysis of the growth plate following irradiation with and without radioprotection. J. Bone Joint Surg. (Am.) 85: 1302, 2003.
12. Margulies, B., Morgan, H., Allen, M., Straus, J., Spadaro, J., and Damron, T. Transiently increased bone density after irradiation and the radioprotectant drug amifostine in a rat model. Am. J. Clin. Oncol. 26: e106, 2003.
13. Damron, T. A., Mathur, S., Horton, J. A., et al. Temporal changes in PTHrP, Bcl-2, Bax, caspase, TGF-beta, and FGF-2 expression following growth plate irradiation with or without radioprotectant. J. Histochem. Cytochem. 52: 157, 2004.
14. Matsumura, S., Jikko, A., Hiranuma, H., Deguchi, A., and Fuchihata, H. Effect of x-ray irradiation on proliferation and differentiation of osteoblast. Calcif. Tissue Int. 59: 307, 1996.
15. Matsumura, S., Hiranuma, H., Deguchi, A., Maeda, T., Jikko, A., and Fuchihata, H. Changes in phenotypic expression of osteoblasts after X irradiation. Radiat. Res. 149: 463, 1998.
16. Dare, A., Hachisu, R., Yamaguchi, A., Yokose, S., Yoshiki, S., and Okano, T. Effects of ionizing radiation on proliferation and differentiation of osteoblast-like cells. J. Dent. Res. 76: 658, 1997.
17. Dudziak, M. E., Saadeh, P. B., Mehrara, B. J., et al. The effects of ionizing radiation on osteoblast-like cells in vitro. Plast. Reconstr. Surg. 106: 1049, 2000.
18. Gal,T.J., Munoz-Antonia, T., Muro-Cacho,C.A., and Klotch, D. W. Radiation effects on osteoblasts in vitro: A potential role in osteoradionecrosis. Arch. Otolaryngol. Head Neck Surg. 126: 1124, 2000.
19. Szymczyk, K. H., Shapiro, I. M., and Adams, C. S. Ionizing radiation sensitizes bone cells to apoptosis. Bone 34: 148, 2004.
20. O'Donovan, D. A., Yeung, I., Zeman, V., Neligan, P. C., Pang, C. Y., and Forrest, C. R. Radiation-induced craniofacial bone growth inhibition: Development of an animal model. J. Craniofac. Surg. 12: 533, 2001.
21. Forrest, C. R., O'Donovan, D. A., Yeung, I., et al. Efficacy of radioprotection in the prevention of radiation-induced craniofacial bone growth inhibition. Plast. Reconstr. Surg. 109: 1311, 2002.
22. La Scala, G. C., O'Donovan, D. A., Yeung, I., et al. Radiation-induced craniofacial bone growth inhibition: Efficacy of cytoprotection following a fractionated dose regimen. Plast. Reconstr. Surg. 115: 1973, 2005.
23. Gevorgyan, A. M., La Scala, G. C., Sukhu, B., et al. An in vitro model of radiation-induced craniofacial bone growth inhibition. J. Craniofac. Surg. 18: 1044, 2007.
24. Gevorgyan, A. M., La Scala, G. C., Sukhu, B., et al. Radiation-induced craniofacial bone growth inhibition: In vitro cyto-protection in the rabbit orbito-zygomatic complex periosteum-derived cell culture. Plast. Reconstr. Surg. 121: 763, 2008.
25. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semi-automated colorimetric assay: Assessment of chemosensitiv-ity testing. Cancer Res. 47: 936, 1987.
26. Sabokbar, A., Millett, P. J., Myer, B., and Rushton, N. A rapid, quantitative assay for measuring alkaline phosphatase activity in osteoblastic cells in vitro. Bone Miner. 27: 57, 1994.
27. Bristow, R. G., and Hill, R. P. Molecular and cellular basis of radiotherapy. In I. F. Tannock, R. P. Hill, R. G. Bristow, and L. Harrington (Eds.), The Basic Science of Oncology, 4th Ed. New York: McGraw-Hill, 2004. Pp. 261-288.
28. Bristow, R. G., and Hill, R. P. Comparison between in vitro radiosensitivity and in vivo radioresponse in murine tumor cell lines: II. In vivo radioresponse following fractionated treatment and in vitro/in vivo correlations. Int. J. Radiat. Oncol. Biol. Phys. 18: 331, 1990.
29. Bristow, R. G., Jang, A., Peacock, J., Chung, S., Benchimol, S., and Hill, R. P. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene 9: 1527, 1994.
30. Zhao, Y., Guan, H., Liu, S. F., Wu, R. C., and Wang, Z. Overexpression of QM induces cell differentiation and mineralization in MC3T3-E1. Biol. Pharm. Bull. 28: 1371, 2005.
31. Franceschi, R. T., and Iyer, B. S. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. J. Bone Miner. Res. 7: 235, 1992.
32. Sudo, H., Kodama, H. A., Amagai, Y., Yamamoto, S., and Kasai, S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J. Cell Biol. 96: 191, 1983.
33. Quarles, L. D., Yohay, D. A., Lever, L. W., Caton, R., and Wenstrup, R. J. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: An in vitro model of osteoblast development. J. Bone Miner. Res. 7: 683, 1992.
34. Peterson, W. J., Tachiki, K. H., and Yamaguchi, D. T. Serial passage of MC3T3-E1 cells down-regulates proliferation during osteogenesis in vitro. Cell Prolif. 37: 325, 2004.
35. Wang, D., Christensen, K., Chawla, K., Xiao, G., Krebsbach, P. H., and Franceschi, R. T. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J. Bone Miner. Res. 14: 893, 1999.
36. Faulhaber, O., and Bristow, R. G. Basis of cell kill following clinical radiotherapy. In M. Sluyser (Ed.), Application of Apoptosis to Cancer Treatment. Amsterdam: Springer, 2005. Pp. 293-320.
37. Sweeney, T. R. A Survey of Compounds from the Antiradiation Drug Development Program of the U.S. Washington, D.C.: Walter Reed Army Institute of Research, 1979.
38. Grdina, D. J., Murley, J. S., and Kataoka, Y. Radioprotectants: Current status and new directions. Oncology 63 (Suppl. 2): 2, 2002.
39. Damron, T. A., Spadaro, J. A., Horton, J. A., Margulies, B. S., Straus, J. A., and Farnum, C. E. Novel radioprotectant drugs for sparing radiation-induced damage to the physis. Int. J. Radiat. Biol. 80: 217, 2004.
40. Damron, T. A., Spadaro, J. A., Horton, J. A., Margulies, B. S., Straus, J. A., and Farnum, C. E. Combinations of radioprotectants spare radiation-induced damage to the physis. Clin. Orthop. 426: 110, 2004.
41. Spadaro, J. A., Horton, J. A., Margulies, B. S., et al. Radioprotectant combinations spare radiation-induced damage to the physis more than fractionation alone. Int. J. Radiat. Biol. 81: 759, 2005.
42. Damron, T. A., Horton, J. A., Naqvi, A., et al. Combination radio-protectors maintain proliferation better than single agents by decreasing early parathyroid hormone-related protein changes after growth plate irradiation. Radiat. Res. 165: 350, 2006.
43. Takahashi, S., Sugimoto, M., Kotoura, Y., Sasai, K., Oka, M., and Yamamuro, T. Long-term changes in the haversian systems following high-dose irradiation: An ultrastructural and quantitative histomorphological study. J. Bone Joint Surg. (Am.) 76: 722, 1994.
44. Mooteri, S. N., Podolski, J. L., Drab, E. A., et al. WR-1065 and radioprotection of vascular endothelial cells: II. Morphology. Radiat. Res. 145: 217, 1996.
45. Rubin, D. B., Drab, E. A., Kang, H. J., et al. WR-1065 and radioprotection of vascular endothelial cells: I. Cell proliferation, DNA synthesis and damage. Radiat. Res. 145: 210, 1996.
46. Khodarev, N. N., Kataoka, Y., Murley, J. S., Baumann, F. E., and Blazek, E. R. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int. J. Radiat. Oncol. Biol. Phys. 60: 553, 2004.
47. Murley, J. S., Kataoka, Y., Weydert, C. J., Oberley, L. W., and Grdina, D. J. Delayed radioprotection by nuclear transcription factor kappaB-mediated induction of manganese super-oxide dismutase in human microvascular endothelial cells after exposure to the free radical scavenger WR1065. Free Radic. Biol. Med. 40: 1004, 2006.
48. Poggi, M. M., Coleman, C. N., and Mitchell, J. B. Sensitizers and protectors of radiation and chemotherapy. Curr. Probl. Cancer 25: 334, 2001.
49. Grdina, D. J., Nagy, B., Hill, C. K., Wells, R. L., and Paraino, C. The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells. Carcinogenesis 6: 929, 1985.
50. Fouladi, M., Stempak, D., Gammon, J., et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer 92: 914, 2001.
51. Souid, A. K., Fahey, R. C., Dubowy, R. L., Newton, G. L., and Berstein, M. L. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: Drug and thiol levels in plasma and blood cells. A Pediatric Oncology Group study. Cancer Chemother. Pharmacol. 44: 498, 1999.
52. Bonner, H. S., and Shaw, L. M. New dosing regimens for amifostine: A pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J. Clin. Pharmacol. 42: 166, 2002.